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OBJECTIVE—Glycated hemoglobin has been suggested to be superior to fasting glucose for
the prediction of vascular disease and death from any cause. The aim of the present work was to
analyzeandcomparethepredictivevalueofglycatedhemoglobinandfastingglucoseonall-cause
and cause-speciﬁc mortality in subjects who underwent coronary angiography.
RESEARCH DESIGN AND METHODS—We studied 2,686 participants of the Ludwig-
shafen Risk and Cardiovascular health study without a history of diabetes. The majority of this
cohort had coronary artery disease. Glycated hemoglobin was measured at the baseline exam-
ination. The mean (6 SD) duration of the follow-up for all-cause, cardiovascular, and cancer
mortality was 7.54 6 2.1 years.
RESULTS—Atotalof508deathsoccurredduringthefollow-up.Ofthose,299wereaccounted
for by cardiovascular diseases and 79 by cancer. Baseline glycated hemoglobin was predictive of
all-cause, cardiovascular, and cancer mortality. The multivariable-adjusted hazard ratios (HR)
(95% CI) for glycated hemoglobin values of ,5.0, 5.0–5.4, 5.5–5.9, 6.0–6.4, 6.5–7.4, and
$7.5% for all-cause mortality were 1.36 (0.85–2.18), 1.00 (0.76–1.32), 1.00 (reference), 1.11
(0.88–1.41), 1.39 (1.07–1.82), and 2.15 (1.32–3.53), respectively. Similar J-shaped relation-
ships were found between glycated hemoglobin and cardiovascular and cancer mortality. The
associations of glycated hemoglobin with all-cause and cardiovascular mortality remained sig-
niﬁcant after inclusion of fasting glucose as a covariate. However, fasting glucose was not sig-
niﬁcantly related to mortality when adjusting for glycated hemoglobin.
CONCLUSIONS—Glycated hemoglobin signiﬁcantly and independently of fasting glucose
predicts all-cause and cardiovascular mortality in whites at intermediate to high cardiovascular
risk.
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T
he glycated hemoglobin concentra-
tion is a measure of the 2–3-month
average endogenous exposure to
glucose. It has low intraindividual
variability and can be determined in the
nonfasting state (1). Therefore, glycated
hemoglobin is used for the estimation of
glucose control in subjects with known
diabetes(2,3).Recently,glycatedhemoglo-
bin has also been included in the diagnosis
algorithm of diabetes because it indicates
the risk of microvascular disease (4).
Selvin et al. (5) demonstrated in par-
ticipants of the Atherosclerosis Risk In
Communities study who did not have a
historyofdiabetesthatglycatedhemoglo-
bin was also a strong predictor of future
diabetes, cardiovascular disease, and all-
cause mortality.Inthiscommunity-based
cohort of middle-aged white and black
subjects, the predictive value of glycated
hemoglobin was superior to the prognos-
tic information of fasting glucose (5). It
was of particular interest that they
foundaJ-shapedassociationbetweengly-
cated hemoglobin and death from any
cause (5). Compelling explanations for
this observation have not been provided.
Thus, the authors suggested further ex-
ploration of health risks associated with
low-normal glycemia and of confounders
affecting glycated hemoglobin values.
This work aimed to investigate and
compare the predictive values of glycated
hemoglobin and fasting glucose on all-
cause and cardiovascular mortality in
whites who underwent coronary angiog-
raphy. Another objective was to analyze
the relationship of glycated hemoglobin
with death from cancer. Furthermore, we
were interested in metabolic traits and
comorbidity associated with low-normal
glycemic state that might implicate in-
creased risk of mortality. We studied
participants of the Ludwigshafen Risk
and Cardiovascular (LURIC) health study
without a history of diabetes (6). The ma-
jority of this cohort had coronary artery
disease (CAD) (6).
RESEARCH DESIGN AND
METHODS
Study design and participants
LURIC was designed to investigate meta-
bolic and genetic cardiovascular risk fac-
tors. A total of 3,316 patients were
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ORIGINAL ARTICLErecruited between July 1997 and January
2000attheLudwigshafenHeartCenterin
South-WestGermany(6).Inclusioncrite-
riawereasfollows:Germanancestry;clin-
ical stability, with the exception of acute
coronary syndromes; and the availability
of a coronary angiogram. The indications
for angiography in individuals in clini-
cally stable condition were chest pain
and/or noninvasive test results consistent
with myocardial ischemia. Individuals
suffering from any acute illness other
than acute coronary syndromes, chronic
noncardiac diseases, or malignancy
within the past 5 years and those unable
to understand the purpose of the study
were excluded. Subjects with a history
of type 1 or type 2 diabetes and subjects
with incomplete laboratory measure-
ments were additionally excluded, result-
ing in 2,686 subjects for the present
analyses. The cause of death was not
known in 15 decedents, and these sub-
jectswereexcludedwhentheassociations
ofglycatedhemoglobinwithcardiovascu-
lar mortality and cancer mortality were
investigated. The study was approved by
the ethics committee at the Ärztekammer
Rheinland-Pfalz and was conducted in
accordance with the Declaration of
Helsinki. Informed written consent was
obtained from all participants (6). CAD
wasdiagnosedifthecoronaryangiograms
showed stenoses of one or more vessels
$50%. The severity of CAD was quanti-
ﬁed with the Friesinger score (FS) (7).
Maximal luminal narrowing was esti-
mated by visual analysis (6). Oral glucose
tolerancetests(OGTT)wereperformedin
1,772 subjects with fasting glucose ,126
mg/dL.Diabeteswasdiagnosedaccording
to the 2009 criteria of the American Di-
abetes Association (ADA) (8). Hyperten-
sion was diagnosed if the systolic and/or
diastolic blood pressure exceeded 140
and/or 90 mmHg or if there was a history
of hypertension, evident through the use
of antihypertensive drugs (6). We used
the Charlson comorbidity index, which
has been shown to be a valid and reliable
instrumenttoassesscomorbidity,toform
three groups of patients with 0 score
points (group 0), 1 score point (group 1),
and 2 or more score points (group 2) (9).
The study participants were asked to self-
assess the degree of their physical activity
on a semiquantitative scale ranging from
1 to 11, whereby the extremes of this
scale were labeled as sedentary (avoid
walking or exertion) or regular heavy ex-
ercise. They were grouped according to
the following three categories of physical
activity: below average (score, 1–3), av-
erage (score, 4–7), and above average
(score, 8–11).
Follow-up
There was a follow-up for all-cause, car-
diovascular, and cancer mortality. The
mean (6 SD) time of the follow-up was
7.5462.1 years. Information on thevital
statuswasobtainedfromlocalpersonreg-
istries.Deathcertiﬁcateswereusedforthe
classiﬁcation of the causes of death. Two
experienced clinicians who were blinded
to any data of the study participants in-
dependently classiﬁed the causes of
death. In cases of a disagreement or un-
certainty concerning the coding of a spe-
ciﬁc cause of death, classiﬁcation was
made by a principal investigator of the
LURIC study (W.M.) (6).
Laboratory analyses
The standard laboratory methods have
been described (6). Glycated hemoglobin
was measured with an immunoassay (he-
moglobin A1c UNIMATE 5; Hoffmann-
LaRoche, Grenzach-Whylen, Germany).
Glucose was measured enzymatically on a
Hitachi 717 analyzer (Roche, Mannheim,
Germany). Insulin was analyzed with an
immunoenzymometric assay on an AIA
pack IRI/AIA 1200 analyzer (Eurogenetics,
Eschborn, Germany).
Statistical analysis
We formed six categories of glycated
hemoglobin (,5, 5–5.4, 5.5–5.9, 6.0–
6.4, 6.5–7.4, and $7.5%). The baseline
clinical and biochemical characteristics
are presented according to the categories
of glycated hemoglobin. In the case of
continuous variables, we report means
with standard deviations or medians
with interquartile ranges. Categorical
data are expressed as numbers and per-
centages.Comparisonsamongtheglycated
hemoglobin categories were made with
the x2-test for categorical data and with
ANOVA for continuous data. The associ-
ation of glycated hemoglobin with newly
diagnosed type 2 diabetes was also ana-
lyzed with logistic regression using three
predeﬁnedmodelsofadjustment(model1:
unadjusted; model 2: adjusted for sex
a n da g e ;a n dm o d e l3 :a d j u s t e df o rs e x ,
age, and BMI). The results for these anal-
yses are presented as odds ratios with
95% CI. We additionally analyzed the
associations of glycated hemoglobin with
fasting glucose with linear regression. Tri-
glycerides, insulin, and C-reactive protein
(Shapiro-Wilk W test) were transformed
logarithmically before being used in para-
metric statistical procedures. Cox propor-
tionalhazardsmodelswereusedtotestthe
relationships of the glycated hemoglobin
categories with all-cause, cardiovascular,
and cancer mortality. Four predeﬁned
models of adjustment were used (model
1: unadjusted; model 2: adjusted for sex
and age; model 3: adjusted for sex, age,
BMI, hypertension, smoking, glomerular
ﬁltration rate, triglycerides, LDL choles-
terol,HDL cholesterol,and FS;and model
4: model 3 with additional adjustment for
fasting glucose). Glycated hemoglobin
category 5.5–5.9% was used as reference
becausethissubgroupwasthelargest.The
results for these analyses are presented as
hazard ratios (HR) with 95% CI. We also
analyzed the relationships of fasting glu-
cose categories (,100, 100–125, and
$126 mg/dL) with mortality data using
Cox proportional hazards models. Again,
four predeﬁned models of adjustment
were used (model 1–3: as mentioned
above; model 4: model 3 with additional
adjustment for glycated hemoglobin),and
the results are presented as HR with 95%
CI. In addition, adjusted survival curves
based on Cox proportional hazards mod-
els (model 3) were calculated for the rela-
tionships of the glycated hemoglobin and
fasting glucose categories with all-cause
andcardiovascularmortality.Allstatistical
tests were two-sided, and P , 0.05 was
considered signiﬁcant. The SPSS 15.0 sta-
tistical package (SPSS, Inc., Chicago, IL)
was used.
RESULTS
Baseline characteristics according to
categories of glycated hemoglobin
Thedistributionofsexwassimilaramong
theﬁvecategoriesofglycatedhemoglobin
(Table 1). Age, BMI, waist circumference,
fasting glucose and insulin, triglycerides,
and C-reactive protein increased across
the categories of glycated hemoglobin
(Table 1). In agreement, glycated hemo-
globin used as a continuous variable was
signiﬁcantlycorrelatedwithfastingglucose
(r = 0.470; P , 0.001; Supplementary
Fig. 1). Glomerular ﬁltration rate and
HDL cholesterol were inversely related
to the categories of glycated hemoglobin
(Table1).Hypertensionwasmorefrequent
insubjects with high glycated hemoglobin
(Table 1). Type 2 diabetes was newly
diagnosed in 468 (17.4%) of the 2,686
LURIC participants without a history of
diabetes based on fasting glucose and
OGTT. There was a strong association of
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Glycated hemoglobin and mortalityelevated glycated hemoglobin with in-
creased risk of new onset type 2 diabetes.
This relationship was independent of sex,
age, and BMI (Table 1 and Supplementary
Table 1). The proportion of subjects
with CAD (stenoses of one or more
vessels $50%) was higher than 60% for
allglycatedhemoglobincategories. Prev-
alent CAD (stenoses of one or more
vessels$50%)wasnotsigniﬁcantlyrelated
to the categories of glycated hemoglobin.
However, the FS as a more precise mea-
sure of CAD was signiﬁcantly increased in
subjects with high glycated hemoglobin
(Table 1). The Charlson comorbidity
Table 1—Baseline characteristics according to categories of glycated hemoglobin
,5% 5–5.4% 5.5–5.9% 6.0–6.4% 6.5–7.4% $7.5% P*
Number 112 481 868 752 400 73
Glycated hemoglobin (%) 4.7 6 0.2 5.2 6 0.1 5.7 6 0.1 6.2 6 0.1 6.8 6 0.3 8.3 6 0.9 —
Sex: male 88 (78.6) 347 (72.1) 618 (71.2) 504 (67.0) 286 (71.5) 54 (74.0) 0.097
Age (years) 55.5 6 13.0 59.7 6 11.2 61.5 6 10.7 62.8 6 10.6 64.0 6 9.1 66.1 6 9.4 ,0.001
BMI (kg/m
2) 26.1 6 3.9 26.8 6 3.9 27.0 6 3.7 27.3 6 3.8 28.3 6 4.2 28.6 6 4.1 ,0.001
Waist circumference (cm)† 95 6 12 97 6 12 97 6 12 99 6 11 101 6 11 104 6 12 ,0.001
Fasting glucose (mg/dL) 96 6 13 97 6 13 100 6 14 103 6 14 113 6 20 144 6 39 ,0.001
Fasting insulin (mU/L)‡ 7.0 (5.0–13.0) 9.0 (6.0–13.0) 8.0 (6.0–12.0) 9.0 (6.0–14.0) 11 (7–17) 10 (6–19) ,0.001§
Newly diagnosed type 2 diabetes
All 8 (7.1) 43 (8.9) 89 (10.3) 113 (15.0) 158 (39.5) 57 (78.1) ,0.001
Fasting glucose $126 mg/dL 2 (1.8) 14 (2.9) 23 (2.6) 47 (6.3) 91 (22.8) 53 (72.6) ,0.001
Glucose 2 h $200 mg/dL|| 6 (5.4) 29 (6.0) 66 (7.6) 66 (8.8) 67 (16.7) 4 (7.0) ,0.001
Systemic hypertension 64 (57.1) 308 (64.0) 592 (68.2) 546 (72.6) 304 (76.0) 63 (86.3) ,0.001
Blood lipid level (mg/dL)
LDL cholesterol 109 6 29 117 6 34 117 6 33 121 6 35 118 6 34 112 6 34 0.004
HDL cholesterol 41 6 12 39 6 11 40 6 11 40 6 11 38 6 10 37 6 10 ,0.001
Triglycerides 139 (100–195) 138 (101–188) 136 (104–190) 147 (109–197) 153 (114–207) 151 (121–228) ,0.001§
Glomerular ﬁltration rate
(mL/min/1.73 m
2)9 0 6 19 85 6 17 84 6 18 80 6 18 79 6 17 78 6 16 ,0.001
C-reactive protein (mg/L)¶ 3.8 (0.7–7.7) 3.1 (0.8–7.7) 3.4 (0.6–8.7) 4.0 (1.2–9.7) 5.3 (1.8–12.2) 5.7 (2.7–14.3) ,0.001§
Smoking 0.255
Never smoking 31 (27.7) 170 (35.3) 331 (38.1) 278 (37.0) 128 (32.0) 22 (30.1) —
Past smoking 54 (48.2) 207 (43.0) 372 (42.9) 310 (41.2) 186 (46.5) 38 (52.1) —
Current smoking 27 (24.1) 104 (21.6) 165 (19.0) 164 (21.8) 86 (21.5) 13 (17.8) —
Charlson comorbidity index# ,0.001
Group 0 36 (33.6) 163 (35.9) 272 (34.9) 212 (31.8) 92 (26.0) 9 (12.9) —
Group 1 45 (42.1) 169 (37.2) 287 (36.8) 221 (33.2) 127 (35.9) 33 (47.1) —
Group 2 26 (24.3) 122 (26.9) 220 (28.2) 233 (35.0) 135 (38.1) 28 (40.0) —
History of myocardial
infarction 47 (42.0) 190 (39.5) 340 (39.2) 288 (38.3) 160 (40.0) 39 (53.4) 0.242
CAD (50% stenosis) 69 (61.6) 304 (63.2) 550 (63.4) 500 (66.5) 277 (69.3) 56 (76.7) 0.063
FS 5 (1–7) 4 (1–8) 5 (1–8) 5 (2–8) 6 (3–8) 6 (3–10) 0.001
NYHA functional class 0.057
1 56 (50.0) 268 (55.7) 503 (57.9) 379 (50.4) 196 (49.0) 32 (43.8) —
2 36 (32.1) 143 (29.7) 230 (26.5) 221 (29.4) 131 (32.8) 22 (30.1) —
3 18 (16.1) 58 (12.1) 110 (12.7) 130 (17.3) 62 (15.5) 16 (21.9) —
4 2 (1.8) 12 (2.5) 25 (2.9) 22 (2.9) 11 (2.8) 3 (4.1) —
Physical activity** 0.010
Below average 10 (9.2) 34 (7.2) 38 (4.5) 38 (5.2) 29 (7.4) 11 (15.3) —
Average 76 (69.7) 326 (69.2) 610 (72.0) 547 (74.5) 283 (72.0) 45 (62.5) —
Above average 23 (21.1) 111 (23.6) 199 (23.5) 149 (20.3) 81 (20.6) 16 (22.2) —
Medication use
b-Blocker 71 (63.4) 301 (62.6) 558 (64.3) 485 (64.5) 251 (62.8) 44 (60.3) 0.952
ACE inhibitor 49 (43.8) 211 (43.9) 438 (50.5) 407 (54.1) 214 (53.5) 50 (68.5) ,0.001
Calcium antagonist 10 (8.9) 71 (14.8) 116 (13.4) 116 (15.4) 56 (14.0) 15 (20.5) 0.263
Diuretic 25 (22.3) 87 (18.1) 168 (19.4) 204 (27.1) 137 (34.3) 32 (43.8) ,0.001
Statin 47 (42.0) 222 (46.2) 397 (45.7) 388 (51.6) 210 (52.5) 40 (54.8) 0.032
Acetyl salicylic acid 78 (69.6) 343 (71.3) 603 (69.5) 536 (71.3) 284 (71.0) 56 (76.7) 0.822
Values are means (SD) or medians (interquartile ranges) in cases of continuous variables and numbers (percentages) in cases of categorical variables. *x
2-Test for
categoricaldataandANOVAforcontinuousdata;†number:108/475/852/741/397/73;‡number:111/463/849/738/395/71;§ANOVAoflogarithmicallytransformed
values; ||number: 86/348/613/504/208/13; ¶number: 112/481/867/750/399/73; #number: 107/454/779/666/354/70; **number: 109/471/847/734/393/72. NYHA,
New York Heart Association.
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Silbernagel and Associatesindex was positively correlated with the
glycated hemoglobin categories (Table
1). The proportion of subjects with phys-
ical activity below average was increased
insubjectswithhighglycatedhemoglobin
(Table 1). The use of statins, ACE inhibi-
tors, and diuretics was more frequent in
subjects with high glycated hemoglobin
(Table 1).
Association of glycated hemoglobin
and fasting glucose with mortality
A total of 508 (18.9%) deaths occurred
during the follow-up. Of those, 299
(58.9%) were accounted for by cardio-
vascular diseases, and 79 (15.6%) were
attributed to cancer.
All-cause mortality. Death from any
c a u s eo c c u r r e di n2 0( 1 7 . 9 % ) ,7 6
(15.9%), 141 (16.2%), 148 (19.7%), 97
(24.3%), and 26 (35.6%) individuals of
the glycated hemoglobin categories ,5,
5–5.4, 5.5–5.9, 6.0–6.4, 6.5–7.4, and
$7.5%, respectively. Compared with
the glycated hemoglobin category 5.5–
5.9%, subjects in the highest category of
glycated hemoglobin were at signiﬁcantly
elevated risk of death from any cause.
Thisassociationremainedsigniﬁcantafter
multivariateadjustment(Table2andFig.1).
Even inclusion of fasting glucose as a co-
variatedidnotaffectthesigniﬁcanceofthe
results(Table2).Weobservedatrendfora
J-shaped relationship between the glycated
hemoglobin categories and death from
any cause (Table 2). Fasting glucose cat-
egories were also signiﬁcantly related to
all-causemortalityinmultivariatemodels
(Table 3 and Supplementary Fig. 2). How-
ever, signiﬁcance was lost when we addi-
tionally adjusted for glycated hemoglobin
(Table 3).
Cardiovascular mortality. A total of 11
(9.8%), 50 (10.4%), 72 (8.4%), 92
(12.3%), 57 (14.4%), and 17 (23.3%)
subjects of the glycated hemoglobin cat-
egories,5,5–5.4,5.5–5.9,6.0–6.4,6.5–
7.4, and $7.5%, respectively, died from
cardiovascular diseases. Compared with
glycated hemoglobin category 5.5–5.9%,
subjects in the highest category of gly-
cated hemoglobin were more likely to
die from cardiovascular diseases using
univariate and multivariate models, in-
cludingtheFSandfastingglucoseascovar-
iates (Table 2 and Fig. 1). Fasting glucose
categories were also predictive of cardio-
vascular mortality(Table 3).However,the
associations of fasting glucose categories
with cardiovascular mortality did not
remain signiﬁcant after multivariate ad-
justment (Table 3 and Supplementary
Fig. 2).
Cancer mortality. Death from cancer
o c c u r r e di n5( 4 . 5 % ) ,1 0( 2 . 1 % ) ,2 3
(2.7%), 18 (2.4%), 19 (4.8%), and 4
(5.5%) subjects of the of the glycated
hemoglobin categories ,5, 5–5.4, 5.5–
5.9, 6.0–6.4, 6.5–7.4, and $7.5%,
respectively.Increasedglycatedhemoglo-
bin was signiﬁcantly correlated with
higher cancer mortality (Table 2).When
fasting glucose was included as an addi-
tional covariate, the association of the
glycatedhemoglobincategorieswithcan-
cer mortality reached borderline signiﬁ-
cance (Table 2). The relationship of the
fasting glucose categories with cancer
mortality did not reach statistical signiﬁ-
cance (Table 3).
CONCLUSIONS—The main ﬁndings
of this study in patients who predomi-
nantly had CAD are as follows. First,
glycated hemoglobin is a signiﬁcant pre-
dictor of all-cause, cardiovascular, and
cancer mortality showing trends toward
J-shaped associations with all three end
points. Second, the relationships of gly-
c a t e dh e m o g l o b i nw i t ha l l - c a u s ea n d
Table 2—Mortality according to categories of glycated hemoglobin
HbA1c (%)
Model 1* Model 2† Model 3‡ Model 4§
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
All-cause mortality
,5.0 1.08 (0.68–1.72) 0.751 1.48 (0.92–2.36) 0.105 1.36 (0.85–2.19) 0.198 1.36 (0.85–2.18) 0.200
5.0–5.4 0.93 (0.71–1.23) 0.621 1.02 (0.77–1.35) 0.888 1.00 (0.76–1.32) 0.996 1.00 (0.76–1.32) 0.992
5.5–5.9 1.0 reference — 1.0 reference — 1.0 reference — 1.0 reference —
6.0–6.4 1.24 (0.98–1.56) 0.072 1.17 (0.92–1.47) 0.196 1.11 (0.88–1.41) 0.365 1.11 (0.88–1.41) 0.364
6.5–7.4 1.59 (1.23–2.06) ,0.001 1.43 (1.10–1.85) 0.007 1.39 (1.07–1.81) 0.014 1.39 (1.07–1.82) 0.015
$7.5 2.64 (1.74–4.02) ,0.001 2.12 (1.39–3.22) ,0.001 2.12 (1.39–3.25) 0.001 2.15 (1.32–3.53) 0.002
Cardiovascular mortality||
,5.0 1.16 (0.61–2.18) 0.657 1.55 (0.82–2.92) 0.179 1.43 (0.75–2.71) 0.275 1.42 (0.75–2.70) 0.279
5.0–5.4 1.20 (0.84–1.72) 0.325 1.32 (0.92–1.89) 0.137 1.29 (0.90–1.85) 0.168 1.29 (0.90–1.85) 0.173
5.5–5.9 1.0 reference — 1.0 reference — 1.0 reference — 1.0 reference —
6.0–6.4 1.51 (1.11–2.05) 0.009 1.44 (1.05–1.96) 0.022 1.34 (0.98–1.83) 0.063 1.35 (0.99–1.84) 0.066
6.5–7.4 1.84 (1.30–2.60) 0.001 1.66 (1.17–2.35) 0.004 1.58 (1.11–2.24) 0.011 1.59 (1.11–2.28) 0.011
$7.5 3.36 (1.98–5.71) ,0.001 2.73 (1.61–4.64) ,0.001 2.72 (1.59–4.66) ,0.001 2.86 (1.54–5.31) 0.001
Cancer mortality||
,5.0 1.67 (0.63–4.38) 0.302 2.24 (0.85–5.93) 0.103 1.98 (0.75–5.27) 0.170 2.03 (0.76–5.40) 0.156
5.0–5.4 0.76 (0.36–1.59) 0.460 0.83 (0.39–1.74) 0.617 0.81 (0.38–1.70) 0.575 0.82 (0.39–1.72) 0.595
5.5–5.9 1.0 reference — 1.0 reference — 1.0 reference — 1.0 reference —
6.0–6.4 0.93 (0.50–1.71) 0.803 0.88 (0.47–1.63) 0.685 0.94 (0.50–1.75) 0.845 0.93 (0.50–1.74) 0.824
6.5–7.4 1.93 (1.05–3.54) 0.035 1.73 (0.94–3.18) 0.077 1.97 (1.06–3.65) 0.032 1.85 (0.98–3.48) 0.058
$7.5 2.53 (0.88–7.32) 0.087 2.07 (0.72–6.01) 0.180 2.32 (0.79–6.86) 0.127 1.67 (0.46–6.11) 0.438
HR (95% CI) calculated with Cox proportional hazards model. *Unadjusted. †Adjusted for sex and age. ‡Adjusted for sex, age, BMI, hypertension, smoking,
glomerular ﬁltration rate, triglycerides, LDL cholesterol, HDL cholesterol, and FS. §Adjusted for sex, age, BMI, hypertension, smoking, glomerular ﬁltration rate,
triglycerides, LDL cholesterol, HDL cholesterol, FS, and fasting glucose. ||Death certiﬁcates were missing for 15 subjects.
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Glycated hemoglobin and mortalitycardiovascular mortality are independent
of fasting glucose. Third, the association
of fasting glucose with mortality is not
signiﬁcant when glycated hemoglobin is
included as a covariate. Finally, high gly-
cated hemoglobin is strongly associated
with increased risk of new onset diabetes
diagnosed according to the ADA criteria
of 2009 (8).
Several previous studies have dem-
onstrated continuous positive correla-
tions of glycated hemoglobin with
mortality and even subclinical cardiovas-
cular disease in subjects without a history
of diabetes (10–15). However, in the Ath-
erosclerosisRiskInCommunitiesstudy,a
J-shaped relationship between glycated
hemoglobin and all-cause mortality was
observed (5). Similarly, U-shaped rela-
tionships of glycated hemoglobin with
all-cause and cause-speciﬁc mortality, in-
cluding death from cardiovascular dis-
eases and cancer, were found in a large
New Zealand collective (16). These data
were supported by a study in insurance
applicants (17). We also observed a trend
toward a J-shaped correlation between
glycated hemoglobin and mortality in
our cohort of subjects at intermediate-
to-highcardiovascularrisk.Inagreement,
analyses in the Aerobics Center Longitu-
dinal Study and the San Antonio Heart
Study showed an association between
low fasting glucose and increased all-
cause and cardiovascular mortality (18).
Lowglycated hemoglobinandlowfasting
glucose potentially reﬂect chronic con-
sumingillnessthatmayleadtoearlydeath
(18). Apart from that, the lowest glycated
hemoglobin quintile was prima vista
characterized by a favorable cardiovascu-
larriskfactorproﬁleandlowcomorbidity
Figure 1—Survival curves for (A)a l l - c a u s ea n d( B) cardiovascular mortality calculated with Cox proportional hazards models (model 3)
according to categories of glycated hemoglobin (1: ,5%, 2: 5–5.4%, 3: 5.5–5.9%, 4: 6.0–6.4%, 5: 6.5–7.4%, and 6: $7.5%).
Table 3—Mortality according to categories of fasting glucose
Fasting glucose (mg/dL)
Model 1* Model 2† Model 3‡ Model 4§
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
All-cause mortality
,100 1.0 reference — 1.0 reference — 1.0 reference — 1.0 reference —
100–125 1.18 (0.98–1.42) 0.080 1.08 (0.90–1.30) 0.417 1.12 (0.93–1.36) 0.228 1.10 (0.91–1.33) 0.350
$126 1.56 (1.17–2.08) 0.002 1.33 (0.99–1.77) 0.055 1.39 (1.03–1.87) 0.034 1.16 (0.83–1.63) 0.379
Cardiovascular mortality||
,110 1.0 reference — 1.0 reference — 1.0 reference — 1.0 reference —
100–125 1.25 (0.98–1.59) 0.067 1.14 (0.90–1.45) 0.288 1.17 (0.92–1.50) 0.203 1.14 (0.89–1.46) 0.304
$126 1.55 (1.06–2.27) 0.024 1.31 (0.90–1.92) 0.165 1.35 (0.90–2.01) 0.143 1.09 (0.70–1.71) 0.693
Cancer mortality||
,100 1.0 reference — 1.0 reference — 1.0 reference — 1.0 reference —
100–125 1.39 (0.87–2.22) 0.168 1.27 (0.79–2.03) 0.322 1.40 (0.87–2.27) 0.170 1.34 (0.83–2.18) 0.231
$126 1.71 (0.82–3.56) 0.153 1.47 (0.70–3.06) 0.308 1.81 (0.84–3.90) 0.131 1.34 (0.56–3.21) 0.507
HR (95% CI) calculated with Cox proportional hazards model. *Unadjusted. †Adjusted for sex and age. ‡Adjusted for sex, age, BMI, hypertension, smoking,
glomerular ﬁltration rate, triglycerides, LDL cholesterol, HDL cholesterol, and FS. §Adjusted for sex, age, BMI, hypertension, smoking, glomerular ﬁltration rate,
triglycerides, LDL cholesterol, HDL cholesterol, FS, and glycated hemoglobin. ||Death certiﬁcates were missing for 15 subjects.
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Silbernagel and Associatesas reﬂected by the Charlson comorbidity
index.
A main objective was to compare the
predictive value of fasting glucose and
glycated hemoglobin in participants of
the LURIC study.Itis noteworthy that we
were able to conﬁrm that the association
of glycated hemoglobin with mortality is
independent of fasting glucose but not
vice versa. This ﬁnding suggests that
glycated hemoglobin may be superior to
fasting glucose in the prediction of mor-
tality (5).
Finally, our data conﬁrm that gly-
cated hemoglobin is strongly correlated
with new onset or future type 2 diabetes
diagnosed according to the ADA criteria
of 2009 (5,19–22). However, type 2 dia-
betes was also diagnosed in 7.1% of the
LURIC participants belonging to the low-
est glycated hemoglobin category. This
proportion is markedly increased com-
pared with the 0.8% reported by Selvin
et al. (5). The difference between the two
studiesisaccounted for bythe fact that we
performed OGTT in the majority of the
LURIC participants with fasting glucose
levels ,126 mg/dL. Based on fasting glu-
cose levels, new onset type 2 diabetes
would have been diagnosed in 1.8% of
the LURIC participants in the lowest gly-
cated hemoglobin category only (5). Be-
cause postchallenge glucose is associated
with prognosis (23), our data conﬁrm the
ﬁndings by Woerle et al. (24) that OGTT
will help to identify subjects with in-
creased cardiovascular risk.
Somelimitationspertaintoourstudy.
Considering the racial and ethnic differ-
ences in the glycated hemoglobin con-
centration, our ﬁndings are restricted to
whites(25).Furthermore,theLURICpar-
ticipants have been recruited at a tertiary
referral center and underwent coronary
angiography; therefore, the results may
not be representative of a random popu-
lation sample. However, the aim of this
workwasto speciﬁcally address the ques-
tion whether glycated hemoglobin was a
signiﬁcant and independent predictor of
mortalityinsubjectswithelevatedcardio-
vascular risk. Because this study was ob-
servational in design, we are not able to
prove causality either. In addition, the
number of participants in the subgroup
with the lowest glycated hemoglobin val-
ues was not very large. This may account
for the nonsigniﬁcant association of low-
normal glycemic state with mortality.
Nevertheless, the number of participants
in the highest glycated hemoglobin cate-
gory was even smaller compared with the
lowest category, and a high level of signif-
icance was achieved by analyzing the
mortality data for this subgroup. Another
aspect to be mentioned is that glycated
hemoglobin was only measured once at
baseline. Hence, we were not able to con-
trolforpossiblealterationsofglycatedhe-
moglobin during the follow-up. Finally,
the questionnaire used to estimate physi-
cal activity has not been stringently vali-
dated. The major strengths of the LURIC
cohort are the precise clinical and meta-
bolic characterization of the participants,
including the availability of coronary an-
giograms,itscross-sectionaland prospec-
tive design, and the completeness of the
follow-up.
Inconclusion,wefoundthatglycated
hemoglobin signiﬁcantly and indepen-
dentlyoffastingglucosepredictsall-cause
and cardiovascular mortality in individuals
who underwent coronary angiography.
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